What is the 13F Pro Quality Score for VCEL?

13F Pro ranks Vericel Corp (VCEL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VCEL's current score at https://13fpro.ai/company/VCEL (free sign-up required for the full ranking).

Which hedge funds own the most VCEL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VCEL include BlackRock,, STATE STREET, CONGRESS ASSET MANAGEMENT CO /MA. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/VCEL as soon as new 13F filings post.

Where does 13F Pro source VCEL data?

All Vericel Corp fundamentals and ownership data come directly from SEC EDGAR. Vericel Corp files with the SEC under CIK 887359. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VCEL in?

Vericel Corp (VCEL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives VCEL's revenue?

Per Vericel Corp's latest 10-Q filed with the SEC on 2026-07-30, the biggest revenue drivers are: MACI implants, kits, and instruments ($65.5M, +22.5% YoY); Epicel ($10.4M, +20.8% YoY); NexoBrid ($1.5M, +32.5% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/VCEL.

What are VCEL's largest expenses?

Vericel Corp's latest 10-Q reports these as the largest expense items: Selling, general and administrative ($48.5M, +15.7% YoY); Cost of product sales ($21.1M, +26.6% YoY); Research and development ($7.5M, +11.3% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is VCEL research updated on 13F Pro?

VCEL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Vericel Corp(VCEL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 887359 VCEL stock profile & AI dashboard →

13F Pro Quality Score

62.8/100

Rank #683 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

84.6/100

Profitability

69.5/100

Balance Sheet

70.4/100

Earnings Quality

89.3/100

Free Cash Flow

73.2/100

Institutional Flow

16.8/100

Revenue Scale

29.8/100

Dilution Risk

12.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why VCEL Scores 63/100

exact factor attribution · 2026-09-11

VCEL's composite is driven by revenue growth and earnings quality, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.9 pts

85th pct

Earnings quality

+3.9 pts

89th pct

Free cash flow

+3.5 pts

73th pct

Profitability

+2.9 pts

70th pct

Capital efficiency

+2.0 pts

70th pct

Earnings growth

+0.1 pts

53th pct

Institutional flow

-1.7 pts

17th pct

Shareholder dilution

-1.9 pts

12th pct

Scale

-3.0 pts

30th pct

Latest change (2026-07-30): 46 → 53 · ↑ Profit margin 29→55; ↑ Free cash flow 65→79; despite ↓ Revenue growth 78→65

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

VCEL Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Vericel Corp (VCEL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VCEL at 62.8/100 on a 32-signal composite quality model, placing it at rank #683 of 2,961 stocks — the top 25% of the AI-ranked universe. VCEL scores in the top quartile across earnings quality (89.3), revenue growth (84.6). Areas of concern include institutional flow (16.8) and revenue scale (29.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Vericel Corp reports quarterly revenue of $77.5M, net income of $2.2M, an operating margin of 0.6%. Top institutional holders of VCEL by reported 13-F value include BlackRock, STATE STREET, CONGRESS ASSET MANAGEMENT, based on the most recent SEC filings. VCEL trades on the Nasdaq exchange and files with the SEC under CIK 887359. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VCEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vericel Corp directly from SEC EDGAR. Vericel Corp's 13F Pro composite quality score has ranged between 29 and 67 since 2021, currently 62.8 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Vericel Corp

Quirks, history, and lore behind VCEL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Michigan.
2
The Numbers
Annual revenue in the low hundreds of millions — modest in size, but growing fast in a niche where the addressable patient population is measured in thousands, not millions.
3
The History
Built around cell therapy technologies originally developed in academic and clinical settings, the company commercialized treatments that had been in development for decades before reaching patients.
4
The Secret
Its products aren't pills or devices — they are living cells grown outside the body and implanted back in, making manufacturing more like farming than factory work.
5
The Lore
One of its flagship products, MACI, repairs damaged knee cartilage using a patient's own cells seeded onto a collagen membrane — a favorite among injured athletes who'd rather not have a metal knee at 35.
6
The Giveaway
Its other key product, Epicel, grows permanent skin grafts from a postage-stamp-sized biopsy to cover catastrophic burn wounds — a literal life-saving cell culture business.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving VCEL's Business? Latest 10-Q Breakdown

AI-extracted from Vericel Corp's 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Vericel reported Q2 revenue of $77.5M (+22.5% YoY), achieving operating income of $0.4M versus a loss of $2.0M in Q2 2025, driven by MACI and Epicel volume growth.

Biggest Revenue Drivers

MACI implants, kits, and instruments$65.5M+22.5% YoY

MACI volume and price growth, including strong adoption of MACI Arthro arthroscopic delivery since Q3 2024 launch.

Epicel$10.4M+20.8% YoY

Epicel revenue growth from volume and price increases.

Biggest Revenue Drivers

Total revenue: $77.5M+22.5% YoY

MACI implants, kits, and instruments$65.5M+22.5% YoY

MACI volume and price growth, including strong adoption of MACI Arthro arthroscopic delivery since Q3 2024 launch.

Epicel$10.4M+20.8% YoY

Epicel revenue growth from volume and price increases.

NexoBrid$1.5M+32.5% YoY

Increased adoption by specialty distributors and burn centers following pediatric indication expansion in August 2024.

Largest Expense Items

Selling, general and administrative$48.5M+15.7% YoY

Increase due to higher headcount and employee expenses including MACI sales force expansion, marketing programs, and higher facility costs from Burlington, MA facility.

Cost of product sales$21.1M+26.6% YoY

Increased product sales volume with primarily fixed manufacturing cost structure consisting mainly of labor and facility costs.

Research and development$7.5M+11.3% YoY

Higher headcount and employee expenses, regulatory support for potential MACI launch in United Kingdom, and MACI MASCOT trial spend.

Watch Items from the Filing

Accumulated deficit of $380.4M as of June 30, 2026. Company had net loss of $4.1M for six months ended June 30, 2026, though Q2 achieved net income of $2.2M.
MACI revenue highly concentrated in specialty pharmacies (Orsini and AllCare). Subject to third-party payer reimbursement variability; allowance for uncollectible consideration is $9.8M as of June 30, 2026.
NexoBrid manufacturing conducted by MediWound primarily in Israel; certain raw materials sourced from Taiwan. Exposure to geopolitical risks in Middle East and Taiwan, which could disrupt supply.
BARDA agreement signed March 31, 2026 valued at up to $196.9M over ten years; base period encompasses $34.9M in funding for NexoBrid procurement, VMI establishment, and development. No revenue recorded in Q2 2026.
Burlington, MA manufacturing facility received FDA approval in March 2026 for MACI commercial manufacturing; company began transitioning to this facility as primary MACI manufacturer, supporting long-term capacity and potential international expansion.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$77.5M

Net Income

Q2 2026

$2.2M

Free Cash Flow

Q2 2026

$14.3M

Operating Margin

Q2 2026

0.6%

ROIC

Q2 2026

0.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+16.5% YoY

$276.3MFY 2025

FY22 $164.4MFY23 $197.5MFY24 $237.2MFY25 $276.3M

Net Income

+59.4% YoY

$16.5MFY 2025

FY22 $-16.7MFY23 $-3.2MFY24 $10.4MFY25 $16.5M

Operating Income

+144.4% YoY

$11.0MFY 2025

FY22 $-17.1MFY23 $-6.5MFY24 $4.5MFY25 $11.0M

EPS (Diluted)

+60.0% YoY

$0.32FY 2025

FY22 $-0.35FY23 $-0.07FY24 $0.20FY25 $0.32

Total Assets

+12.8% YoY

$488.0MFY 2025

FY22 $273.0MFY23 $353.7MFY24 $432.7MFY25 $488.0M

Op. Cash Flow

-10.8% YoY

$51.9MFY 2025

FY22 $17.7MFY23 $35.3MFY24 $58.2MFY25 $51.9M

Free Cash Flow

+525.9% YoY

$24.7MFY 2025

FY22 $10.1MFY23 $15.3MFY24 $-5.8MFY25 $24.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$276.3M +16.5%	$237.2M +20.1%	$197.5M +20.2%	$164.4M +5.2%	$156.2M +25.8%	$124.2M
Net Income	$16.5M +59.4%	$10.4M +425.6%	$-3.2M +81.0%	$-16.7M -123.7%	$-7.5M -360.9%	$2.9M
Operating Income	$11.0M +144.4%	$4.5M +169.9%	$-6.5M +62.1%	$-17.1M -117.2%	$-7.9M -431.1%	$2.4M
EPS (Diluted)	$0.32 +60.0%	$0.20 +385.7%	$-0.07 +80.0%	$-0.35 -118.7%	$-0.16 -366.7%	$0.06
Total Assets	$488.0M +12.8%	$432.7M +22.4%	$353.7M +29.5%	$273.0M +12.0%	$243.7M +18.5%	$205.6M
Operating Cash Flow	$51.9M -10.8%	$58.2M +64.7%	$35.3M +99.6%	$17.7M -39.1%	$29.0M +65.3%	$17.6M
Free Cash Flow	$24.7M +525.9%	$-5.8M -138.0%	$15.3M +51.6%	$10.1M -52.2%	$21.1M +41.3%	$14.9M

Get alerted when VCEL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vericel Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VCEL

BlackRock, Inc.
$360.0M8,092,226 sh
STATE STREET CORP
$146.6M3,293,975 sh
CONGRESS ASSET MANAGEMENT CO /MA
$129.7M2,916,295 sh
VANGUARD CAPITAL MANAGEMENT LLC
$100.4M2,255,728 sh
Conestoga Capital Advisors, LLC
$92.7M2,083,832 sh
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$88.7M1,992,855 sh
BNP Paribas Asset Management Holding S.A.
$73.0M1,639,988 sh
GW&K Investment Management, LLC
$69.0M1,550,497 sh
Soleus Capital Management, L.P.
$64.9M1,459,152 sh
GEODE CAPITAL MANAGEMENT, LLC
$59.7M1,341,244 sh

Fund	Value	Shares
BlackRock, Inc.	$360.0M	8,092,226
STATE STREET CORP	$146.6M	3,293,975
CONGRESS ASSET MANAGEMENT CO /MA	$129.7M	2,916,295
VANGUARD CAPITAL MANAGEMENT LLC	$100.4M	2,255,728
Conestoga Capital Advisors, LLC	$92.7M	2,083,832
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	$88.7M	1,992,855
BNP Paribas Asset Management Holding S.A.	$73.0M	1,639,988
GW&K Investment Management, LLC	$69.0M	1,550,497
Soleus Capital Management, L.P.	$64.9M	1,459,152
GEODE CAPITAL MANAGEMENT, LLC	$59.7M	1,341,244

Companies Similar to VCEL

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

VCYT

VERACYTE, INC.

AI score

Very similar · 28 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Champlain Investment Partners, LLC Summit Creek Advisors LLC

LMAT

LEMAITRE VASCULAR INC

AI score

Very similar · 23 shared holders

Conestoga Capital Advisors, LLC CONGRESS ASSET MANAGEMENT CO /MA GENEVA CAPITAL MANAGEMENT LLC

LGND

LIGAND PHARMACEUTICALS INC

AI score

Similar quality profile · 25 shared holders

CONGRESS ASSET MANAGEMENT CO /MA LOOMIS SAYLES & CO L P abrdn plc

LIVN

LivaNova PLC

AI score

Similar quality profile · 19 shared holders

CONGRESS ASSET MANAGEMENT CO /MA Soleus Capital Management, L.P.WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC

KRYS

Krystal Biotech, Inc.

AI score

Similar quality profile · 25 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Soleus Capital Management, L.P.TimesSquare Capital Management, LLC

INSP

Inspire Medical Systems, Inc.

AI score

Similar quality profile · 13 shared holders

Soleus Capital Management, L.P.abrdn plc Susquehanna Portfolio Strategies, LLC

RGEN

REPLIGEN CORP

AI score

Similar quality profile · 21 shared holders

CONGRESS ASSET MANAGEMENT CO /MA Conestoga Capital Advisors, LLC WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC

TMDX

TransMedics Group, Inc.

AI score

Similar quality profile · 10 shared holders

CONGRESS ASSET MANAGEMENT CO /MA FRONTIER CAPITAL MANAGEMENT CO LLC BROWN CAPITAL MANAGEMENT LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VCEL on your watchlist

Track score changes the day Vericel Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VCEL a good stock to buy?

13F Pro's AI-powered analysis of Vericel Corp (VCEL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VCEL are available on the VCEL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VCEL is classified as a small company.

Which hedge funds own VCEL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VCEL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vericel Corp's investment landscape.